Introduction {#section5-1745506520922760}
============

The 'smoker's paradox' is an observational phenomenon of an unexpected favorable outcome after thrombolysis.^[@bibr1-1745506520922760],[@bibr2-1745506520922760]^ Several mechanisms have been proposed to support the phenomenon, including greater thrombotic component in the plaque with comparatively less atherosclerotic plaque burden,^[@bibr3-1745506520922760]^ which is more susceptible to complete reperfusion.^[@bibr4-1745506520922760]^ The existence of the smoker's paradox phenomenon is controversial. Given the inconsistent evidence, the current study investigates possible facilitators of this relationship and whether it can be explained by the difference in demographic and clinical characteristics. Although cigarette smoking is known to be directly linked with the recanalization and reperfusion in tobacco smokers treated with recombinant tissue plasminogen activator (rtPA) for ischemic stroke,^[@bibr5-1745506520922760]^ the danger of smoking is shown in the observed incidence of stroke many years earlier in smokers compared to nonsmokers.^[@bibr6-1745506520922760]^ The favorable response to thrombolytic therapy in smokers with higher rates of recanalization was attributed to the hypercoagulable state of arterial occlusions in smokers.^[@bibr7-1745506520922760],[@bibr8-1745506520922760]^ Therefore, smoking induced hypercoagulation,^[@bibr9-1745506520922760]^ which regulates hematocrit and fibrin-rich clots, enhances fibrinogen levels, and inhibits endogenous fibrinolytic capability.^[@bibr10-1745506520922760]^ Moreover, smoking is associated with an increased plasma level modulated by carbon monoxide.^[@bibr11-1745506520922760],[@bibr12-1745506520922760]^ In turn, carbon monoxide, which is a gasotransmitter, triggers ischemic preconditioning and reinforces endogenous cellular cytoprotective responses to ischemic tissue damage.^[@bibr13-1745506520922760]^ Among nonsmokers, classified as "not ever smokers," "infrequent smokers," and "passive smokers,"^[@bibr14-1745506520922760]^ cardio-embolism occurred more often compared to smokers.^[@bibr6-1745506520922760]^ Cardioembolic strokes are characterized by large territorial infarcts with an extended time in the formation of a tough thrombus, which is a hard clot made of fibrin and platelets found inside the blood vessel that obstructs the flow of blood, which causes a risk of hemorrhage resulting in negative clinical outcomes.^[@bibr15-1745506520922760]^ Therefore, noncardioembolic strokes may be independently associated with positive outcomes in smokers treated with thrombolysis therapy.^[@bibr6-1745506520922760],[@bibr14-1745506520922760]^ This implies that if there are few cardio-embolism patients treated with thrombolytic therapy, the benefit of smoking will be higher in the stroke population. This explains the idea of favorable outcomes in smokers (smoking paradox), an indication of a link between smoking and an improved clinical outcome in stroke patients treated with thrombolytic therapy.

Furthermore, National Institutes of Health Stroke Scale (NIHSS) on admission is known as an independent predictor of functional recovery, whereas such a link between smoking status and outcome has yet to be established. Therefore, it is not clear whether the observed differences in clinical outcome, the inclusion or exclusion for thrombolysis therapy in smokers and nonsmokers with acute ischemic stroke, are attributed to clinical risk factors at pretreatment or the differential effects of smoking. In general, cigarette smoking and its major subtypes in all individuals are a major independent risk factor for stroke in both men and women.^[@bibr16-1745506520922760]^ The risk of stroke is known to be greater among female smokers compared to males who smoke,^[@bibr14-1745506520922760]^ indicating that the proportion of male and female smokers in acute ischemic stroke may not be the same. The first objective is to determine differences between the respective male and female populations of stroke patients with a history of smoking. In the general population, male and female stroke patients do not present with the same exclusion criteria for thrombolysis therapy.^[@bibr17-1745506520922760][@bibr18-1745506520922760]--[@bibr19-1745506520922760]^ For instance, since the risk of stroke is greater in women with a history of smoking, a higher proportion of female stroke patients with a history of smoking can therefore be excluded from intravenous thrombolytic therapy. Therefore, the second objective is to determine whether more pretreatment clinical risk factors will contribute to the exclusion of more female compared to male stroke patients with a history of smoking. Understanding the exclusion clinical risk factors of rtPA for both men and women with stroke and a history of smoking could help identify the association between smoking and stroke outcome. In addition, it could help identify future research target to improve thrombolysis in stroke patients with a history of smoking.

Methods {#section6-1745506520922760}
=======

Data collection {#section7-1745506520922760}
---------------

This study used data from acute ischemic stroke patients between January 1, 2010, and June 30, 2016, from the Greenville Health System (GHS). A total of 4665 ischemic stroke patients were identified. Of this population, 1446 patients were eligible for rtPA and 3219 were not. Of the 1,446 acute ischemic stroke patients eligible for rtPA, 379 present with a history of smoking. The GHS stroke registry is well standardized in accordance with the Get With The Guidelines (GWTG)-Stroke registry designed by the American Heart Association (AHA) and the American Stroke Association (ASA) in a combined effort to increase the quality of care for stroke patients.^[@bibr20-1745506520922760]^ Previous studies^[@bibr21-1745506520922760],[@bibr22-1745506520922760]^ reported the full description of this registry, and approval for this study was obtained from the Institutional Review Board (IRB) ethical committee. Briefly, a standardized data collection method was developed to collect data on pretreatment factors such as stroke evaluation that considered NIH scores, and ambulatory status including the ability to walk on admission, during admission, and after discharge. Other variables include language/aphasia, arm deficit on admission, care indicators to measure compliance (such as stroke unit care and evaluations by allied health), and health results (including discharge destination and dependence at discharge). Clinical risk factors were retrospectively abstracted from patients' medical records: coronary artery disease (CAD), carotid stenosis, diabetes, dyslipidemia, atrial fibrillation/flutter, congestive heart failure (CHF), hypertension, transient ischemic attack (TIA) or previous stroke, smoking history, peripheral vascular disease (PVD), and neurological status at the time of presentation. Additional data such as in-hospital procedures, treatments, evidence of antithrombotic treatment, contraindications to anticoagulant, and discharge guidelines were collected retrospectively. All data submitted to GHS stroke registry went through an extensive quality and detailed evaluations. This involves using established protocol to ascertain the quality of the data and to avoid several types of errors including the interpretation or coding of data.

Statistical analysis {#section8-1745506520922760}
--------------------

Our sample consisted of 379 acute ischemic stroke patients with a history of smoking. Patients' data were deidentified and divided into two groups based on receipt of rtPA---rtPA group (included for treatment) and no rtPA group (excluded from treatment).

Following the analysis of gender differences between the rtPA exclusion and the inclusion rtPA group, further analysis was determined using a multivariate analysis. Variables associated in the univariate analysis with P \< 0.05 representing statistical significance were incorporated into a stepwise logistic regression model to determine variables independently associated with exclusion or inclusion (adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were considered) in the total study population as well as in the male and female subgroups. We added other variables including NIHSS score and age as continuous variables in the model. The goal is to identify demographic and clinical characteristics associated with exclusion from rtPA administration in the total study population as well as in the male and female subgroups. In the regression model, rtPA treatment was used as the dependent variable. In addition, gender was included as the primary independent variable in the regression model for the whole ischemic stroke population with a history of smoking, while the male and female subcohorts were analyzed separately. Although smoking was an inclusion criterion in the model, it may not appear in the final stepwise regression model if it was not significantly associated with the dependent variable in order to meet the criteria for stepwise consideration. In our analysis, the predictor variables for each logistic regression model were selected by stepwise regression and variables with P \< 0.05 remained in the model. All statistical analyses were performed utilizing SAS version 9.4, and statistical significance was established at P \< 0.05 for all group comparisons.

Results {#section9-1745506520922760}
=======

A total of 379 stroke patients with a history of smoking were examined, of which 181 received rtPA while 198 were excluded from rtPA. Baseline demographic and clinical characteristics of rtPA and non-rtPA groups are presented in [Table 1](#table1-1745506520922760){ref-type="table"}. Patients excluded from rtPA tended to be older (59.52 ± 11.48 vs 56.69 ± 12.25, P = 0.02) with a lower NIHSS (7.23 ± 6.34 vs 9.41 ± 6.36, P \< 0.01). Patients with a history of dyslipidemia, atrial fibrillation, previous TIA, carotid artery stenosis, antiplatelet medication, and weakness/paresis on initial examination were associated with exclusion from rtPA in stroke patients with a history of smoking.

###### 

Characteristics of acute ischemic stroke patients with a history of smoking stratified by rtPA. Continuous variables are represented as mean ± S.D. and comparisons between groups are made with a Student's *t* test. Discrete variables are represented as count (percent frequency), and comparisons between groups were made using Pearson's chi-square test.
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  ---------------------------------------------------------------------------------------------------
  N = 379                            rtPA\                  No rtPA\                    P value
                                     (181; control group)   (198; experimental group)   
  ---------------------------------- ---------------------- --------------------------- -------------
  Age group: (%)                                                                        

   \< 50                             45 (55.56)             36 (44.44)                  0.4733

   50--59                            61 (48.03)             66 (51.97)                  

   60--69                            50 (45.87)             59 (54.13)                  

   70--79                            20 (40.82)             29 (59.18)                  

   ⩾ 80                              5 (38.46)              8 (61.54)                   

  Mean ± SD                          56.69 ± 12.25          59.52 ± 11.84               0.0239\*

  Race: (%)                                                                             

   Caucasian                         136 (48.06)            147 (51.94)                 0.5534

   African-American                  44 (46.32)             51 (53.68)                  

  Gender: (%)                                                                           

   Male                              110 (47.21)            123 (52.79)                 0.7877

   Female                            71 (48.63)             75 (51.37)                  

  Body mass index (%)                                                                   

   \< 18.5                           10 (50.00)             10 (50.00)                  0.9397

   18.5--24.9                        55 (45.83)             65 (54.17)                  

   25--29.9                          62 (50.82)             60 (49.18)                  

   30--34.9                          25 (43.10)             33 (56.90)                  

   35--39.9                          18 (50.00)             18 (50.00)                  

   ⩾ 40                              11 (47.83)             12 (52.17)                  

   Mean ± SD                                                                            

  Medical history: (%)                                                                  

   Hypertension                                                                         

    Yes                              137 (48.93)            143 (51.07)                 0.4426

    No                               44 (44.44)             55 (55.56)                  

   Coronary artery disease                                                              

    Yes                              51 (52.58)             46 (47.42)                  0.2706

    No                               130 (46.10)            152 (53.90)                 

   Dyslipidemia                                                                         

    Yes                              93 (52.84)             83 (47.160                  0.0651\*

    No                               88 (43.35)             115 (56.65)                 

   Atrial fibrillation/flutter                                                          

    Yes                              9 (29.03)              22 (70.97)                  0.0294\*

    No                               172 (49.43)            176 (50.57)                 

   Previous stroke                                                                      

    Yes                              48 (41.74              67 (58.26)                  0.1216

    No                               133 (50.38)            131 (49.62)                 

   Previous TIA                                                                         

    Yes                              28 (68.29)             13 (31.71)                  0.0053\*

    No                               153 (45.27)            185 (54.73)                 

   Congestive heart failure                                                             

    Yes                              12 (37.50)             20 (62.50)                  0.2247

    No                               169 (48.70)            178 (51.30)                 

   Carotid artery stenosis                                                              

    Yes                              3 (15.00)              17 (85.00)                  0.0026\*

    No                               178 (49.58)            181 (50.42)                 

   Peripheral vascular disease                                                          

    Yes                              9 (39.13)              14 (60.87)                  0.3928

    No                               172 (48.31)            184 (51.69)                 

   Diabetes                                                                             

    Yes                              43 (45.26)             52 (54.74)                  0.574

    No                               138 (48.590            146 (51.41)                 

  Medication history: (%)                                                               

   Antiplatelet                                                                         

    Yes                              84 (54.90)             69 (45.10)                  0.0220\*

    No                               97 (42.92)             129 (57.08)                 

   Antihypertensive                                                                     

    Yes                              119 (50.85)            115 (49.15)                 0.1251

    No                               62 (42.76)             83 (57.24)                  

   Cholesterol reducer medications                                                      

    Yes                              73 (51.05)             70 (48.95)                  0.318

    No                               108 (45.76)            128 (54.24)                 

   Diabetes medication                                                                  

    Yes                              33 (47.83)             36 (52.17)                  0.9899

    No                                                                                  

  Initial NIH stroke scale           148 (47.74)            162 (52.26)                 

  Group: (%)                                                                            

   0--9                              109 (43.60)            141 (56.40)                 

   10--14                            30 (55.56)             24 (44.44)                  

   15--20                            24 (52.17)             22 (47.83)                  

   21--25                            18 (62.07)             11 (37.93)                  

  Mean ± SD                          9.41 ± 6.36            7.23 ± 6.34                 0.0009\*

  Risk of mortality GWTG                                                                

  Mean ± SD                          4.46 ± 4.41            3.66 ± 3.92                 0.0776

  Initial exam findings: (%)                                                            

   Weakness/paresis                                                                     

    Yes                              174 (52.41)            158 (47.59)                 \< 0.0001\*

    Not Improved                     7 (14.89)              40 (85.11)                  

   Altered level of consciousness                                                       

    Yes                              44 (41.12)             63 (58.88)                  0.1048

    Not improved                     137 (50.37)            135 (49.63)                 

   Aphasia/language disturbance                                                         

    Yes                              117 (48.55)            124 (51.45)                 0.6839

    No                               64 (46.38)             74 (53.62)                  

  Ambulation improvement                                                                

   Improved                          124 (53.68)            107 (46.32)                 0.0039\*

   Not improved                      57 (38.51)             91 (61.49)                  

  Location of treatment: (%)                                                            

   Specialized stroke unit           105 (46.05)            123 (53.95)                 0.4225

   Non-specialized stroke unit       75 (51.02)             72 (48.98)                  

   Missing                           1 (25.00)              3 (75.00)                   
  ---------------------------------------------------------------------------------------------------

SD: standard deviation; TIA: transient ischemic attack; NIH: National Institutes of Health; GWTG: Get With The Guidelines.

[Table 2](#table2-1745506520922760){ref-type="table"} presents acute ischemic stroke patients with a history of smoking characterized by rtPA status and by gender. A total of 75 female and 123 male stroke patients with a history of smoking were excluded from rtPA. In the no rtPA group (versus the rtPA group), females had higher rates of previous stroke (65.12% vs 34.9%), carotid artery stenosis (100% vs 0%), and usage of a cholesterol reduction medication (61.8% vs 38.2 %). At the time of presentation, they had a lower calculated NIHSS score (6.95 ± 6.05 vs 8.99 ± 6.35) and lower rates of weakness/paresis (46.9 % vs 53.1%). In male stroke patient smokers, excluded patients presented with lower rates of CAD (41.8% vs 58.2%), dyslipidemia (42.9% vs 57.1%), previous TIA (14.3% vs 85.7%), antiplatelet medication use (38.7% vs 61.3%), and use of a cholesterol reducer (40.9% vs 59.1%). At the time of presentation, they also had a lower calculated NIHSS score (7.41 ± 6.53 vs 9.69 ± 6.39) and lower rates of weakness/paresis (48% vs 52%).

###### 

Demographic and clinical characteristics of acute ischemic stroke patients with a history of smoking stratified by rtPA and gender. Continuous variables are represented as mean ± S.D. and comparisons between groups are made with a Student's *t* test. Discrete variables are represented as count (percent frequency) and comparisons between groups were made using Pearson's chi-square test.
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                                    Female smokers (146)   P value         Male smokers (233)   P value                        
  --------------------------------- ---------------------- --------------- -------------------- --------------- -------------- ----------
  Age group: (%)                                                                                                               
   \< 50                            24 (58.54)             17 (41.46)      0.2293               47 (52.22)      19 (47.50)     0.5422
   50--59                           14 (37.84)             23 (62.16)                           29 (40.28)      43 (47.78)     
   60--69                           21 (56.76)             16 (43.24)                           10 (41.67)      43 (59.72)     
   70--79                           10 (40.00)             15 (60.00)                           21 (52.50)      14 (58.33)     
   ⩾ 80                             2 (33.33)              4 (66.67)                            3 (42.86)       4 (57.14)      
  Mean ± SD                         56.01 ± 14.92          59.55 ± 12.91   0.1277               57.13 ± 10.21   59.5 ± 11.19   0.0931
  Race: (%)                                                                                                                    
   Caucasian                        54 (48.65)             57 (51.35)      0.5799               82 (47.67)      33 (54.10)     Nil
   African-American                 16 (47.06)             18 (52.94)                           28 (45.90)      0              
  Body mass index (%)                                                                                                          
   \<18.5                           4 (33.33)              8 (66.67)       0.5186               6 (75.00)       2 (25.00)      0.2488
   18.5--24.9                       20 (51.28)             19 (48.72)                           35 (43.21)      46 (56.79)     
   25--29.9                         20 (43.48)             26 (56.52)                           42 (55.26)      34 (44.74)     
   30--34.9                         10 (45.45)             12 (54.55)                           15 (41.67)      21 (58.33)     
   35--39.9                         10 (66.67)             5 (33.33)                            8 (38.10)       13 (61.90)     
   ⩾ 40                             7 (58.33)              5 (41.67)                            4 (36.36)       7 (63.64)      
   Mean ± SD                        29.28 ± 7.5            28.1 ± 11.04    0.4518               27.35 ± 5.87    27.9 ± 6.54    0.5031
  Medical history: (%)                                                                                                         
   Hypertension                                                                                                                
   Yes                              50 (46.73)             57 (53.27)      0.4465               87 (50.29)      86 (49.71)     0.1099
   No                               21 (53.85)             18 (46.15)                           23 (38.33)      37 (61.67)     
   Coronary artery disease                                                                                                     
   Yes                              12 (40.00)             18 (60.00)      0.2887               39 (58.21)      28 (41.79)     0.0326\*
   No                               59 (50.86)             57 (49.14)                           71 (42.77)      95 (57.23)     
   Dyslipidemia                                                                                                                
   Yes                              33 (46.48)             38 (53.52)      0.6128               60 (57.14)      45 (42.86)     0.0059\*
   No                               38 (50.670             37 (49.33)                           50 (39.06)      78 (60.94)     
   Atrial fibrillation/flutter                                                                                                 
   Yes                              4 (28.57)              10 (71.43)      0.1143               5 (29.41)       12 (70.59)     0.1268
   No                               67 (50.76)             65 (49.24)                           105 (48.61)     111 (51.39)    
   Previous stroke                                                                                                             
   Yes                              15 (34.88)             28 (65.12)      0.0318\*             33 (45.83)      39 (54.17)     0.7783
   No                               56 (54.37)             47 (45.63)                           77 (47.83)      84 (52.17)     
   Previous TIA                                                                                                                
   Yes                              10 (50.00)             10 (51.590      0.895                18 (85.71)      3 (14.29)      0.0002\*
   No                               61 (48.410             65 (51.59)                           92 (43.40)      120 (56.60)    
   Congestive heart failure                                                                                                    
   Yes                              4 (33.33)              8 (66.67)       0.2684               8 (40.00)       12 (60.00)     0.4993
   No                               67 (50.00)             67 (50.00)                           102 (47.89)     111 (52.11)    
   Carotid artery stenosis                                                                                                     
   Yes                              0 (0.00)               10 (100.00)     0.0014\*             3 (30.00)       7 (70.00)      0.2651
   No                               71 (52.21)             65 (47.79)                           107 (47.98)     116 (47.98)    
   Peripheral vascular disease                                                                                                 
   Yes                              4 (33.33)              8 (66.67)       0.2684               5 (45.45)       6 (54.55)      0.9049
   No                               67 (50.00)             67 (50.00)                           105 (47.30)     117 (52.70)    
   Diabetes                                                                                                                    
   Yes                              15 (38.46)             24 (61.54)      0.1378               28 (50.00)      28 (50.00)     0.6314
   No                               56 (52.34)             51 (47.66)                           82 (46.33)      95 (53.67)     
  Medication history: (%)                                                                                                      
   Antiplatelet                                                                                                                
   Yes                              27 (45.00)             33 (55.00)      0.4635               57 (61.29)      36 (38.71)     0.0005\*
   No                               44 (51.16)             42 (48.84)                           53 (37.86)      87 (62.14)     
   Antihypertensive                                                                                                            
   Yes                              43 (47.25)             48 (52.75)      0.6684               76 (53.15)      67 (46.85)     0.0221\*
   No                               28 (50.91)             27 (49.09)                           34 (37.78)      56 (62.22)     
   Cholesterol reducer medication                                                                                              
   Yes                              21 (38.18)             34 (61.82)      0.0496\*             52 (59.09)      36 (40.91)     0.0047\*
   No                               50 (54.95)             41 (45.05)                           58 (40.00)      87 (60.00)     
   Diabetes medication                                                                                                         
   Yes                              15 (46.88)             17 (53.13)      0.8221               18 (48.65)      19 (51.35)     0.8485
   No                               56 (49.12)             58 (50.88)                           92 (46.94)      104 (53.06)    
  Initial NIH Stroke Scale                                                                                                     
  Group: (%)                                                                                                                   
   0--9                             45 (45.00)             55 (55.00)      0.3637               17 (51.52)      86 (57.33)     0.2688
   10--14                           13 (61.90)             8 (38.10)                            18 (56.25)      16 (48.48)     
   15--20                           6 (42.86)              8 (57.14)                            64 (42.67)      14 (43.75)     
   21--25                           7 (63.64)              4 (36.36)                            11 (61.11)      7 (38.89)      
  Mean ± SD                         8.99 ± 6.35            6.95 ± 6.05     0.0488\*             9.69 ± 6.39     7.41 ± 6.53    0.0076\*
  Risk of mortality GWTG                                                                                                       
  Mean ± SD                         4.18 ± 4.4             3.36 ± 3.81     0.2512               4.65 ± 4.43     3.84 ± 3.99    0.1769
  Initial exam findings: (%)                                                                                                   
  Weakness/paresis                                                                                                             
   Yes                              69 (53.08)             61 (46.92)      0.0022\*             105 (51.98)     97 (48.02)     0.0002\*
   No                               2 (12.50)              14 (87.50)                           5 (16.13)       26 (83.87)     
  Altered level of consciousness                                                                                               
   Yes                              14 (38.89)             22 (61.11)      0.1779               30 (42.25)      41 (57.75)     0.3157
   No                               57 (51.82              53 (48.18)                           80 (49.38)      82 (50.62)     
  Aphasia/language disturbance                                                                                                 
   Yes                              43 (51.19)             41 (48.81)      0.4712               74 (47.13)      83 (52.87)     0.9732
   No                               28 (45.16)             34 (54.84)                           36 (47.37)      40 (52.63)     
  Location of treatment: (%)                                                                                                   
   Specialized stroke unit          0                      1 (100.00)      0.4823               1 (33.33)       2 (66.67)      0.7267
   Nonspecialized stroke unit       30 (52.63)             27 (47.37)                           45 (50.00)      45 (50.00)     
   Missing                          41 (46.59)             47 (53.41)                           64 (45.71)      76 (54.29)     

SD: standard deviation; TIA: transient ischemic attack; NIH: National Institutes of Health; GWTG: Get With The Guidelines.

[Table 3](#table3-1745506520922760){ref-type="table"} presents factors associated with rtPA exclusion in an acute ischemic stroke population with a history of smoking. As shown in the table, seven demographic and clinical characteristics are significantly associated with rtPA exclusion: increasing age (OR = 1.020 95% CI, 1.003--1.037, P \< 0.05), increased rates of atrial fibrillation/flutter (OR = 2.388 95% CI, 1.069--5.332, P \< 0.05), increased rates of carotid artery stenosis (OR = 5.571 95% CI, 1.605--19.338, P \< 0.01), reduced rates of previous TIA (OR = 0.384 95% CI, 0.192--0.767, P \< 0.01), lower NIHSS scores (OR = 0.948, 95% CI, 0.917--0.979, P \< 0.01), and reduced rates of weakness/paresis at the time of presentation (OR = 0.159 95% CI, 0.069--0.365, P \< 0.01).

###### 

Factors associated with rtPA exclusion in acute ischemic stroke patients with a history of smoking. Positive B values (OR \> 1) denote variables more associated with rtPA exclusion, while negative B values (OR \< 1) denote variables more associated with rtPA inclusion.
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  ------------------------------------------------------------------------------
                                           Odds ratio              P value
  ---------------------------------------- ----------------------- -------------
  Age group                                1.020 (1.003--1.037)    0.0239\*

  Race W vs. B                             0.933 (0.585--1.486)    0.7688

  Gender F vs. M                           0.945 (0.624--1.429)    0.7877

  Body mass index                          0.998 (0.972--1.025)    0.8730

  Hypertension Y vs. N                     0.835 (0.527--1.32)     0.4429

  Coronary artery disease Y vs. N          0.771 (0.486--1.225)    0.2709

  Dyslipidemia Y vs. N                     0.683 (0.455--1.025)    0.0655

  Atrial fibrillation/flutter Y vs. N      2.388 (1.069--5.332)    0.0337\*

  Previous stroke                          1.417 (0.911--2.205)    0.1223

  Previous TIA                             0.384 (0.192--0.767)    0.0067\*

  Congestive heart failure                 1.582 (0.750--3.336)    0.2279

  Carotid artery stenosis                  5.571 (1.605--19.338)   0.0068\*

  Peripheral vascular disease              1.454 (0.614--3.446)    0.3951

  Diabetes                                 1.143 (0.717--1.821)    0.5749

  Antiplatelet                             0.618 (0.409--0.934)    0.0223

  Antihypertensive                         0.722 (0.476--1.095)    0.1256

  Cholesterol reducer medication           0.809 (0.534--1.227)    0.3182

  Diabetes medication                      0.997 (0.591--1.680)    0.9899

  Initial NIH Stroke Scale                 0.948 (0.917--0.979)    0.0011\*

  Risk of mortality GWTG                   0.954 (0.905--1.006)    0.0802

  Weakness/paresis Y vs. N                 0.159 (0.069--0.365)    \< 0.0001\*

  Altered level of consciousness Y vs. N   1.453 (0.924--2.285)    0.1056

  Aphasia/language disturbance Y vs. N     0.917 (0.603--1.394)    0.6842

  Risk of mortality GWTG\                  0.954 (0.905--1.006)    0.0802
  Ischemic stroke                                                  

  Stroke unit Y vs. N                      1.220 (0.806--1.848)    0.3474
  ------------------------------------------------------------------------------

TIA: transient ischemic attack; NIH: National Institutes of Health; GWTG: Get With The Guidelines.

Y vs N: Yes vs No.

[Table 4](#table4-1745506520922760){ref-type="table"} presents factors associated with rtPA exclusion or inclusion in male and female acute ischemic stroke patients with a history of smoking. [Table 4](#table4-1745506520922760){ref-type="table"} indicates that only four factors were significantly associated with rtPA exclusion or inclusion in female stroke smokers: increasing rates of previous stroke (OR = 2.224 95% CI, 1.064--4.649, P \< 0.05), use of a cholesterol reducer (OR = 1.947 95% CI, 0.997--3.909, P = 0.05), lower NIHSS scores (OR = 0.948 95% CI, 0.898--1.000, P = 0.05), and reduced rates of weakness/paresis at the time of presentation (OR = 0.126, 95% CI, 0.028--0.578, P \< 0.01). Six factors were significantly associated with rtPA exclusion or inclusion in males: reduced dyslipidemia (OR = 0.481 95% CI, 0.284--0.813, P \< 0.01), reduced rates of previous TIA (OR = 0.128 95% CI, 0.037--0.447, P \< 0.01), reduced rates of antiplatelet use (OR = 0.385 95% CI, 0.224--0.660, P \< 0.01), antihypertensive use (OR = 0.535, 95% CI, 0.313--0.917, P \< 0.05), use of a cholesterol reducer (OR = 0.462, 95% CI, 0.269--0.792, P \< 0.01), lower NIHSS scores (OR = 0.947 95% CI, 0.909--0.986, P \< 0.01), and reduced rates of weakness/paresis at the time of presentation (OR = 0.178 95% CI, 0.066--0.481, P \< 0.01).

###### 

Factors associated with rtPA exclusion in male and female acute ischemic stroke patients with a history of smoking. Positive B values (OR \> 1) denote variables more associated with rtPA exclusion while negative B values (OR \< 1) denote variables more associated with rtPA inclusion.
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                                           Female smokers                       P value    Male smokers           P value
  ---------------------------------------- ------------------------------------ ---------- ---------------------- ----------
  Age group                                1.019 (0.995--1.043)                 0.1286     1.021 (0.996--1.046)   0.0949
  Race W vs. B                             0.938 (0.435--2.025)                 0.8711     0.931 (0.518--1.673)   0.8119
  Gender F vs. M                                                                                                  
  Body mass index                          0.987 (0.952--1.023)                 0.4604     1.014 (0.973--1.058)   0.5015
  Hypertension Y vs. N                     1.330 (0.637--2.774)                 0.4476     0.614 (0.337--1.119)   0.1115
  Coronary artery Disease Y vs. N          1.553 (0.686--3.512)                 0.2907     0.537 (0.302--0.953)   0.0337
  Dyslipidemia Y vs. N                     1.183 (0.617--2.265)                 0.6132     0.481 (0.284--0.813)   0.0062\*
  Atrial Fibrillation/flutter Y vs. N      2.577 (0.769--8.630)                 0.1248     2.269 (0.773--6.660)   0.1358
  Previous stroke                          2.224 (1.064--4.649)                 0.0336\*   1.083 (0.620--1.891)   0.7785
  Previous TIA                             0.938 (0.365--2.411)                 0.8950     0.128 (0.037--0.447)   0.0013\*
  Congestive heart failure                 2.000 (0.575--6.959)                 0.2761     1.378 (0.542--3.508)   0.5007
  Carotid artery stenosis                  \> 999.999 (\< 0.001-- \> 999.999)   0.9703     2.151 (0.543--8.532)   0.2757
  Peripheral vascular disease              2.000 (0.575--6.959)                 0.2761     1.077 (0.319--3.631)   0.9051
  Diabetes                                 1.757 (0.831--3.713)                 0.1400     0.863 (0.473--1.575)   0.6311
  Antiplatelet                             1.280 (0.661--2.481)                 0.4639     0.385 (0.224--0.660)   0.0005\*
  Antihypertensive                         1.158 (0.592--2.262)                 0.6685     0.535 (0.313--0.917)   0.0228\*
  Cholesterol reducer medication           1.974 (0.997--3.909)                 0.0509\*   0.462 (0.269--0.792)   0.0050\*
  Diabetes medication                      1.094 (0.499--2.400)                 0.8223     0.934 (0.462--1.886)   0.8483
  Initial NIH Stroke Scale                 0.948 (0.898--1.000)                 0.0514\*   0.947 (0.909--0.986)   0.0086\*
  Risk category                            0.951 (0.873--1.037)                 0.2540     0.955 (0.894--1.021)   0.1791
  Weakness/paresis Y vs. N                 0.126 (0.028--0.578)                 0.0077\*   0.178 (0.066--0.481)   0.0007\*
  Altered level of consciousness Y vs. N   1.690 (0.785--3.640)                 0.1802     1.333 (0.760--2.340)   0.3163
  Aphasia/language disturbance Y vs. N     0.785 (0.407--1.516)                 0.4715     1.009 (0.583--1.747)   0.9732
  Risk of mortality GWTG                   0.951 (0.873--1.037)                 0.2540     0.955 (0.894--1.021)   0.1791
  Stroke unit Y vs. N                      1.274 (0.653--2.483)                 0.4776     1.187 (0.699--2.018)   0.5254

TIA: transient ischemic attack; NIH: National Institutes of Health; GWTG: Get With The Guideline.

Y vs N: Yes vs No.

Demographic and clinical factors associated with exclusion or inclusion in acute ischemic stroke patients with a history of smoking are presented in [Table 5](#table5-1745506520922760){ref-type="table"}. Following an adjusted analysis for confounding variables, [Table 5](#table5-1745506520922760){ref-type="table"} reveals seven variables that are independently associated with rtPA in acute ischemic stroke patients with a history of smoking. Three variables were more associated with rtPA exclusion: increasing age (OR = 1.024 95% CI, 1.004--1.044, P \< 0.05), atrial fibrillation/flutter (OR = 3.208 95% CI, 1.308--7.868 P \< 0.05), and carotid artery stenosis (OR = 11.419 95% CI 2.904--44.899, P \< 0.01). Four other variables were more associated with rtPA inclusion: higher calculated NIHSS score (OR = 0.960 95% CI, 0.926--0.996, P \< 0.05), history of previous TIA (OR = 0.369 95% CI 0.161--0.844 P \< 0.05), weakness/paresis on initial examination (OR = 0.184 95% CI 0.075--0.450 P \< 0.01), and antiplatelet medication use (OR = 0.406 95% CI 0.246--0.672, P \< 0.01). A similar stepwise conditional logistic regression was performed for the male and female stroke patients with a history of smoking subgroups separately to identify variables that were associated with rtPA exclusion. In the female subgroup ([Table 6](#table6-1745506520922760){ref-type="table"}), only one factor, weakness/paresis on initial examination (OR = 0.117 95% CI 0.025--0.548, P \< 0.01), was associated with rtPA exclusion. In male subgroup patients ([Table 7](#table7-1745506520922760){ref-type="table"}), three factors were independently associated with rtPA exclusion: history of previous TIA (OR = 0.169 95% CI 0.044--0.655, P \< 0.05), antiplatelet medication use (OR = 0.456 95% CI 0.230--0.906, P \< 0.05), and weakness/paresis on initial examination (OR = 0.171 95% CI 0.056--0.521 P \< 0.01).

###### 

Factors associated with acute ischemic stroke patients with a history of smoking. Positive B values (adjusted OR \> 1) denote variables more associated with rtPA exclusion, while negative B values (adjusted OR \< 1) denote variables more associated with rtPA inclusion. Multicollinearity and interactions among independent variables were checked. Hosmer--Lemeshow test (P = 0.9095), Cox & Snell (R^2^ = 0.1702), Max-rescaled R-square (R^2^ = 0.2270), and classification table (overall correctly classified percentage = 67%) were applied to check the model fitness.
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                                        B-value   Adjusted odds ratio      Wald      P value
  ------------------------------------- --------- ------------------------ --------- ----------
  Age                                   0.0234    1.024 (1.004--1.044)     1.4886    0.0184\*
  Initial NIH Stroke Scale              −0.0404   0.960 (0.926--0.996)     4.7512    0.0293\*
  Atrial fibrillation/flutter Y vs. N   1.1655    3.208 (1.308--7.868)     6.4825    0.0109\*
  Previous TIA Y vs. N                  −0.9981   0.369 (0.161--0.844)     5.5766    0.0182\*
  Carotid artery stenosis Y vs. N       2.4353    11.419 (2.904--44.899)   12.1534   0.0005\*
  Weakness/paresis Y vs. N              −1.6952   0.184 (0.075--0.450)     13.7595   0.0002\*
  Antiplatelet Y vs. N                  −0.9007   0.406 (0.246--0.672)     12.2832   0.0005\*

NIH: National Institutes of Health; TIA: transient ischemic attack.

Y vs N: Yes vs No.

###### 

Factors more associated with female acute ischemic stroke patients with a history of smoking. Positive B values (adjusted OR \> 1) denote variables more associated with rtPA exclusion, while negative B values (adjusted OR \< 1) denote variables more associated with rtPA inclusion. Multicollinearity and interactions among independent variables were checked. Hosmer--Lemeshow test (P = 0.9790), Cox & Snell (R^2^ = 0.1147), Max-rescaled R-square (R^2^ = 0.1529), and classification table (overall correctly classified percentage = 58.2%) were applied to check the model fitness.
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                                   Adjusted odds ratio    P value
  -------------------------------- ---------------------- ----------
  Previous stroke Y vs. N          1.877 (0.858--4.108)   0.1150
  Cholesterol reducer medication   1.918 (0.926--3.971)   0.0796
  Weakness/paresis Y vs. N         0.117 (0.025--0.548)   0.0065\*

Y vs N: Yes vs No.

###### 

Factors more associated with male acute ischemic stroke patients with a history of smoking. Positive B values (adjusted OR \> 1) denote variables more associated with rtPA exclusion, while negative B values (adjusted OR \< 1) denote variables more associated with rtPA inclusion. Multicollinearity and interactions among independent variables were checked. Hosmer--Lemeshow test (P = 0.6565), Cox & Snell (R^2^ = 0.1725), Max-rescaled R-square (R^2^ = 0.2303), and classification table (overall correctly classified percentage = 63.5%) were applied to check the model fitness.
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                                   Adjusted odds ratio    P value
  -------------------------------- ---------------------- ----------
  Initial NIH Stroke Scale         0.958 (0.916--1.003)   0.0646
  Previous TIA Y vs. N             0.169 (0.044--0.655)   0.0101\*
  Weakness/paresis Y vs. N         0.171 (0.056--0.521)   0.0019\*
  Antiplatelet Y vs. N             0.456 (0.230--0.906)   0.0249\*
  Cholesterol reducer medication   0.687 (0.353--1.338)   0.2699

NIH: National Institutes of Health; TIA: transient ischemic attack.

Y vs N: Yes vs No.

Discussion {#section10-1745506520922760}
==========

Three major findings arise from this study. First, we found that more ischemic stroke patients with a history of smoking were excluded from rtPA compared to stroke patients with a history of smoking that received thrombolysis therapy. Second, although the number of male smokers was higher than female smokers in the stroke population, there was no significant difference in male and female patients excluded from thrombolysis therapy in the univariate analysis. Third, following adjustment, more clinical risk factor variables were significantly associated with reduced exclusion of male compared to female stroke patients with a history of smoking. This finding suggests that females are more likely to be excluded than males from thrombolysis therapy. Moreover, the effect of the only common factor in males and females (weakness) is stronger in males (17.1 % vs 11.7% less likelihood for rtPA exclusion). The primary outcome of this analysis was clinical risk factors associated with exclusion from rtPA in females and males with acute ischemic stroke and a history of smoking. Other outcomes included individual components of the ischemic stroke and comorbidities associated with stroke or smoking.

In the univariate analysis, female patients with a history of previous stroke, carotid artery stenosis, and use of cholesterol reduction medication were excluded from rtPA. This effect was attenuated in the adjusted analysis in the female patients, indicating that the proportion of exclusion does not depend on the female gender but rather on clinical risk factors within the stroke population. Following adjustment with regression analysis, we found that male patients are less likely to have CAD, dyslipidemia, a previous trans ischemic attack (TIA), weakness, are less likely to take antiplatelet medication or cholesterol reduction medication and have a lower calculated NIHSS score. Several clinical characteristics identified in male stroke patients with a history of smoking are similar to those found in other studies in male stroke patients.^[@bibr23-1745506520922760][@bibr24-1745506520922760][@bibr25-1745506520922760][@bibr26-1745506520922760][@bibr27-1745506520922760]--[@bibr28-1745506520922760]^ For example, we found that after adjusting for age and comorbidities, male stroke patients with a history of smoking with a previous TIA and weakness are more likely to receive rtPA. This is supported by other studies where a previous TIA^[@bibr29-1745506520922760]^ and weakness^[@bibr30-1745506520922760]^ did not affect the favorable outcome following thrombolysis therapy in male stroke patients. In our study, male stroke patients with a history of smoking that take antiplatelet medication had lower odds of receiving thrombolysis therapy. This finding is supported by other studies^[@bibr31-1745506520922760][@bibr32-1745506520922760][@bibr33-1745506520922760][@bibr34-1745506520922760]--[@bibr35-1745506520922760]^ that found the use of antiplatelet medication to be associated with an increased risk of bleeding among female in comparison to male stroke patients. This finding, together with our current result, indicates that the benefits of antiplatelet therapy may be different among male and female stroke patients with a history of smoking.

In the univariate analysis, age was not significant in the female or male patients who did not receive or received thrombolysis. However, the effect of age was significantly associated with exclusion in the whole stroke population following the adjusted analysis and was eliminated in the male or female stroke patients. Therefore, it seems that the unadjusted variables in the acute ischemic stroke smokers' population could have been strongly confounded by several factors including age and related comorbidities. In a stroke population, the mean age of women is higher than that of men,^[@bibr36-1745506520922760]^ but in our study, the mean age of men and women who did not receive rtPA (59.3 vs 59.5) was younger and not significantly different. Therefore, it is possible that our young male and female stroke smoker patients probably combine many comorbid conditions to exclude patients from thrombolysis. Although our patient population also contains elderly men and women (\> 70 years old), the adjusted analysis generally abolished any effect of old age on the male and female population. In general, the risk of stroke is known to be greater among female smokers compared to male smokers,^[@bibr14-1745506520922760]^ lower in women than in men under the age of 75, but similar when comparing women and men above age 75.^[@bibr37-1745506520922760]^ In our study, more clinical risk factors were associated with a less likelihood of excluding more male than female stroke patients with a history of smoking. This finding suggests that the age structure (\< 75) in our stroke population with a history of smoking probably translates into more clinical risk factors, rather than age, to exclude more women than men from thrombolysis therapy. Therefore, gender difference in stroke with a history of smoking related to exclusion risk factors is unlikely to be mediated by differences in smoking-related behavior (such as greater degree of smoking by men or women), because such a gender effect is associated with clinical risk factors of stroke. For example, many stroke-related studies reported that women who survive stroke have less favorable clinical outcomes than men,^[@bibr38-1745506520922760]^ have a worse clinical prognosis than men,^[@bibr39-1745506520922760]^ are more likely to have comorbidities and activity limitations on follow-up,^[@bibr40-1745506520922760]^ and have a lower overall quality of life than men after stroke.^[@bibr16-1745506520922760],[@bibr41-1745506520922760]^ These findings support our current result that the observed differences in exclusion from thrombolysis between women and men stroke patients with a history of smoking may be attributed to pretreatment clinical risk factors that excluded more women than men instead of the differential effects of smoking on men and women. There is no doubt that smoking is a major risk factor for acute ischemic stroke patients and causes damage to both men and women. In addition, the risk of stroke is greater among women smokers compared to men who smoke.^[@bibr16-1745506520922760]^ This finding is supported by our study that in a stroke population with a history of smoking, women are more likely to be excluded from thrombolysis therapy compared to men, even after adjustment.

Several limitations may hamper the interpretation of the results of this study. There is potential under-reporting of smoking status, which could have resulted in misclassification of some current smokers as nonsmokers, resulting in an inaccurately reduced relationship between smoking and stroke risk. Furthermore, lack of information on the duration of smoking did not allow for in-depth analysis for gender differential effects and duration of smoking on stroke. The single-center approach and the retrospective data could introduce a selection bias in the dataset. There was also a lack of data on some clinical risk factors that have a role in stroke onset, including metabolic syndrome, and sex-hormone-related factors. Finally, because information on menopausal status and use of hormone replacement therapies were not available, we were unable to evaluate whether they had any modifying effect on the relationship between smoking and risk of stroke in women. A major strength of this study is the use of data from a large stroke center that provides quality dataset of acute ischemic stroke population with a history of smoking. These data provide the opportunity to develop predictive models to identify clinical risk factors that excluded men and women stroke patients with a history of smoking from thrombolysis therapy. An important contribution of this study to stroke neurology is 1) the investigation of exclusion criteria for rtPA in stroke among women and men with a history of smoking and 2) our finding that observed gender difference in stroke population with a history of smoking is attributed to the pretreatment risk factors that excluded more women than men.

Conclusion {#section11-1745506520922760}
==========

Smokers, irrespective of gender, have an increased risk of incurring a stroke during their lifetime compared to nonsmokers. Our findings suggest that women are more likely to be excluded from thrombolysis therapy compared to men stroke patients with a history of smoking. The exclusion appears to be associated with pretreatment clinical risk factors that excluded more women than men, rather than the effects of smoking on women than men. The observed gender difference suggests that more studies are needed to improve the use of thrombolysis therapy in stroke patients with a history of smoking irrespective of gender.
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